IN BRIEF: PureTech’s Ankili to be acquired by Virtual Therapeutics

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

PureTech Health PLC - London-listed Biotech company headquartered in Boston - Says Tuesday that founded entity, Ankili Inc, a game developer focusing on improving mental health, will merge with Virtual Therapeutics Corp, a Boston-based digital therapeutics company. As of May 7, PureTech owned over 12.5 million of Ankili common stock.

Akili shareholders will receive $0.4340 per share, a 4% premium on Ankili’s May 28 closing price. The transaction is expected to close in the third quarter 2024.

Virtual Therapeutics CEO Dan Elenbaas said the merger will create a leader in the digital mental healthcare industry: ‘Together, we can build a company that brings these behavioural services to as many patients as possible - regardless of where they are or barriers that exist for them today.’

Current share price: 228.50 pence

12-month change: up 0.7%

Copyright 2024 Alliance News Ltd. All Rights Reserved.